CorVue FDA Approval Status
FDA Approved: No
Brand name: CorVue
Generic name: binodenoson
Company: King Pharmaceuticals, Inc.
Treatment for: Diagnosis and Investigation
CorVue (binodenoson) is an investigational cardiac pharmacologic stress SPECT (single-photon-emission computed tomographic) imaging agent intended for use in patients with or at risk for coronary artery disease (CAD) who are unable to perform a cardiac exercise stress test.
In October 2009, King Pharmaceuticals, Inc. announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) advising the company that the New Drug Application (NDA) for CorVue (binodenoson) had not been approved.
Development timeline for CorVue
| Date | Article |
|---|---|
| Oct 21, 2009 | FDA Issues Complete Response Letter for CorVue |
| Dec 19, 2008 | King Pharmaceuticals Announces Submission of New Drug Application for CorVue |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
